A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Inclusion Criteria: 1. Histologically diagnosed high-grade serous or endometrioid recurrent ovarian,fallopian tube,or peritoneal cancer. 2. Patients must have received at least 2 previous platinum-containing regimens. 3. At least one target lesion. 4. ECOG performance status 0-1. 5. Adequate bone marrow, kidney and liver function. Exclusion Criteria: 1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib.For exploratory cohort ，patients who received PARP inhibitor are eligible; 2. Prior malignancy unless curatively treated and disease-free for \> 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix allowed; 3. Radiation or anti-hormonal therapy or anticancer therapy within 14 days before first administration; 4. Known to be human immunodeficiency virus positive; 5. Known active hepatitis C virus, or known active hepatitis B virus; 6. Untreated and/or uncontrolled brain metastases; 7. Patients with clinical symptoms of cancer ascites, pleural effusion, who need to drainage, or who have undergone ascites drainage within 3 months prior to the first administration; 8. Pregnant or breast-feeding women.